EcoDrugPlus

Cholinergic Receptor, Muscarinic 4

Ensembl ID : ENSMSIG00000019816
Gene Symbol: CHRM4
1 Cross references
199 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5

Ensembl ID : ENSMSIG00000007252
Gene Symbol: CHRM5
1 Cross references
278 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha Polypeptide 3

Ensembl ID : ENSMSIG00000004539
Gene Symbol: CHRNA3
1 Cross references
222 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha Polypeptide 4

Ensembl ID : ENSMSIG00000014109
Gene Symbol: CHRNA4
1 Cross references
219 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha Polypeptide 7

Ensembl ID : ENSMSIG00000021069
Gene Symbol: CHRNA7
1 Cross references
258 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Beta Polypeptide 4

Ensembl ID : ENSMSIG00000004549
Gene Symbol: CHRNB4
1 Cross references
213 Possible Orthologues:

Chymase 1, Mast Cell

Ensembl ID : ENSMSIG00000031149
Gene Symbol: CMA1
1 Cross references
306 Possible Orthologues:

Coagulation Factor Ii

Ensembl ID : ENSMSIG00000020083
Gene Symbol: F2
1 Cross references
100 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSMSIG00000011072
Gene Symbol: F2R
1 Cross references
342 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor-Like 3

Ensembl ID : ENSMSIG00000026840
Gene Symbol: F2RL3
1 Cross references
211 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSMSIG00000006688
Gene Symbol: F7
1 Cross references
289 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSMSIG00000006622
Gene Symbol: F10
1 Cross references
252 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).